You are here

Roche Ends Development of Several Drugs

Among them, lampalizumab had fared poorly in phase 3 tests

In an update on pharmaceutical pipeline projects tucked inside its financial results, FierceBiotech reports, Swiss drugmaker Roche announced that it was pulling the plug on several early- and late-stage candidates.

The casualties:

  • Lampalizumab (RG7417), a phase 3 drug that last fall failed two tests: Chroma and Spectri, which were assessing the drug in geographic atrophy due to age-related macular degeneration (AMD) and secondary to AMD. At one point, some analysts had predicted the drug could reach $2 billion in annual sales.
  • RG7986, an antibody drug conjugate for refractory B-cell non-Hodgkin’s lymphoma that was in phase 1 testing.
  • RG6047, which was being tested in phase 1 for metastatic estrogen receptor-positive, HER2-negative breast cancer.
  • RG7203, a small-molecule inhibitor of phosphodiesterase 10A (PDE10A) for the treatment of schizophrenia.

Source: FierceBiotech; February 1, 2018.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation